[1] Goiato MC, Tamae AC, Silva PI, et al. Oral rehabilitation after surgical removal of pleomorphic adenoma[J]. J Craniofac Surg, 2011, 22(6):1996-1999.
[2] Weissferdt A, Moran CA. Pulmonary salivary gland-type tumors with features of malignant mixed tumor (carcinoma ex pleomorphic adenoma): a clinicopathologic study of five cases[J]. Am J Clin Pathol, 2011, 136(5):793-798.
[3] 陈宇, 田鲲, 耿宁, 等. 基质金属蛋白酶及其组织抑制剂在涎腺多形性腺瘤生物学行为中的意义[J].中华口腔医学杂志,2005,40(1):58-61.
[4] Kayano K, Shimada T, Shinomiya T, et al. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2[J]. J Pathol, 2004 , 202(4):403-411.
[5] 许良中,杨文涛. 免疫组织化学反应结果的判断标准[J]. 中国癌症杂志,1996,6(4):229-230.
[6] Sulik A, Chyczewski L. Immunohistochemical analysis of MMP-9, MMP-2 and TIMP-1, TIMP-2 expression in the central nervous system following infection with viral and bacterial meningitis[J]. Folia Histochem Cytobiol, 2008, 46(4):437-442.
[7] Honkavuori-Toivola M, Talvensaari-Mattila A, Soini Y, et al. Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma[J]. Tumour Biol, 2012, 33(4):935-941.
[8] Kondakova IV, Klisho EV, Savenkova OV, et al. Matrix metalloproteinase 2 and 9 as the factor of head and neck tumor metastasis[J]. Biomed Khim, 2008, 54(5):555-560.
[9] Palei AC, Sandrim VC, Cavalli RC, et al. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension[J]. Clin Biochem, 2008, 41(10-11):875-880.
[10] Fiedorczyk M, Klimiuk PA, Sierakowski S, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis[J]. J Rheumatol, 2006, 33(8):1523-1529.
[11] Brun JL, Cortez A, Commo F, et al. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2[J]. Int J Oncol, 2008, 33(6):1239-1246.
[12] Nishida Y, Miyamori H, Thompson EW, et al. Activation of matrix metalloproteinase-2 (MMP-2) by membrane type 1 matrix metalloproteinase through an artificial receptor for proMMP-2 generates active MMP-2[J]. Cancer Res, 2008, 68(21):9096-9104.
[13] Lipari L, Mauro A, Gallina S, et al. Expression of gelatinases (MMP-2, MMP-9) and cyclooxygenases (COX-1, COX-2) in some benign salivary gland tumors[J]. Int J Immunopathol Pharmacol, 2012, 25(1):107-115.
[14] Bildt MM, Bloemen M, Kuijpers-Jagtman AM, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in gingival crevicular fluid during orthodontic tooth movement[J]. Eur J Orthod,2009, 31(5):529-535.
[15] Miyake JA, Benadiba M, Colquhoun A. Gamma-linolenic acid inhibits both tumour cell cycle progression and angiogenesis in the orthotopic C6 glioma model through changes in VEGF, Flt1, ERK1/2, MMP2, cyclin D1, pRb, p53 and p27 protein expression[J]. Lipids Health Dis,2009,8:8.
[16] Droppelmann CA, Gutiérrez J, Vial C, et al. Matrix metalloproteinase-2-deficient fibroblasts exhibit an alteration in the fibrotic response to connective tissue growth factor/CCN2 because of an increase in the levels of endogenous fibronectin[J]. J Biol Chem, 2009, 284(20):13551-13561.
[17] Toden S, Belobrajdic DP, Bird AR, et al. Effects of dietary beef and chicken with and without high amylose maize starch on blood malondialdehyde, interleukins, IGF-I, insulin, leptin, MMP-2, and TIMP-2 concentrations in rats[J]. Nutr Cancer,2010, 62(4):454-465.
[18] Peng B, Cao L, Ma X, et al. Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk[J]. Mutagenesis,2010, 25(4):371-379.
[19] Sampieri CL, de la Pena S, Ochoa-Lara M, et al. Expression of matrix metalloproteinases 2 and 9 in human gastric cancer and superficial gastritis[J]. World J Gastroenterol,2010, 16(12):1500-1505.
[20] 张斌, 孙瑶, 赵尔飏, 等. CD105和MMP-2在腺样囊性癌中表达及预后判断的临床意义[J].口腔颌面外科杂志,2007,17(1):50-55. |